Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Rhea-AI Summary

Context Therapeutics (NASDAQ:CNTX) will present two poster presentations at the Society for Immunotherapy of Cancer 40th Annual Meeting, November 7–9, 2025, in National Harbor, MD.

One poster is a Trial in Progress for the Phase 1, first‑in‑human study of CT-95 (mesothelin x CD3 TCE) in advanced solid tumors (Abstract #586), scheduled Saturday, November 8, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls. The second poster covers preclinical efficacy, safety, and PK data for CT-202 (Nectin-4 x CD3 TCE) (Abstract #963), scheduled Friday, November 7, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls.

Abstracts are available via the SITC 40th Annual Meeting website.

PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two posters will be presented at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, being held November 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD.

Context’s poster presentations will include a Trial in Progress poster for the Phase 1 clinical trial evaluating CT-95, a Mesothelin x CD3 TCE, as well as a poster for preclinical efficacy, safety and pharmacokinetic data regarding Context’s asset, CT-202, a Nectin-4 x CD3 TCE.

Poster Presentation Details:

Title:		Trial in Progress: A Phase 1, First-in-Human Study of CT-95, a mesothelin (MSLN)-Directed Bispecific T Cell engager (TCE) in Subjects with Advanced Solid Tumors
Date and Time:		Saturday, November 8, 2025, 10:00 AM ET
Abstract Number:		586
Location:		Prince George ABC Exhibit Halls

Title:		CT-202: a dual pH-dependent Nectin-4 x CD3 bispecific T cell engager
Date and Time:		Friday, November 7, 2025, 10:00 AM ET
Abstract Number:		963
Location:		Prince George ABC Exhibit Halls

For more information and to view the abstract, visit the SITC 40^th Annual Meeting website.

About CT-95
CT-95 is a mesothelin (“MSLN”) x CD3 TCE bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. One challenge in developing MSLN-targeted therapies has been the presence of MSLN fragments, also referred to as shed MSLN, found in both blood and the tumor microenvironment that can serve as a decoy or sink for MSLN-targeting antibodies. CT-95 is a fully humanized bispecific T cell engager that has a moderate affinity but high avidity for membrane-bound MSLN, that is intended to minimize the impact of the shed MSLN. The clinical trial is being conducted at clinical sites in the US. More information about the CT-95 clinical trial (NCT06756035) can be found on https://clinicaltrials.gov.

About CT-202
CT-202 is a Nectin-4 x CD3 TCE bispecific antibody that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjugate (“ADC”), but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the tumor microenvironment.

About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain SITC presenters to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com

FAQ

What will Context Therapeutics (CNTX) present at SITC 40th Annual Meeting on November 7–9, 2025?

CNTX will present two posters: a Phase 1 Trial in Progress for CT-95 (Abstract #586) and preclinical data for CT-202 (Abstract #963).

When and where is the CT-95 poster (CNTX) scheduled at SITC 2025?

The CT-95 poster is scheduled for Saturday, Nov 8, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls (Abstract #586).

What data will the CT-202 poster (CNTX) present at SITC on Nov 7, 2025?

The CT-202 poster presents preclinical efficacy, safety, and pharmacokinetic data and is scheduled for Nov 7, 2025 at 10:00 AM ET (Abstract #963).

Does the CT-95 presentation from Context (CNTX) include clinical trial details or is it an early announcement?

The CT-95 entry is a Trial in Progress poster for a Phase 1, first‑in‑human study, indicating ongoing early‑phase clinical work.

How can investors access the Context Therapeutics (CNTX) abstracts for SITC 2025?

Abstracts and presentation details are available on the SITC 40th Annual Meeting website.

Will the Context (CNTX) SITC posters include human data for CT-202?

No—CT-202 is presented with preclinical efficacy, safety, and PK data, not clinical human trial results.